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Available online 22 July 2016Hereditary hemochromatosis (HH) is an autosomal recessive disorder characterized by excessive iron absorption
resulting in pathologically increased body iron stores. It is typically associated with common HFE gene mutation
(p.Cys282Tyr and p.His63Asp). However, in Southern European populations up to one third of HHpatients do not
carry the risk genotypes.
This study aimed to explore the use of next-generation sequencing (NGS) technology to analyse a panel of iron
metabolism-related genes (HFE, TFR2, HJV, HAMP, SLC40A1, and FTL) in 87 non-classic HH Portuguese patients.
A total of 1241 genetic alterationswere detected corresponding to 53 different variants, 13 ofwhichwere not de-
scribed in the available public databases. Among them, ﬁve were predicted to be potentially pathogenic: three
novel mutations in TFR2 [two missense (p.Leu750Pro and p.Ala777Val) and one intronic splicing mutation
(c.967-1GNC)], one missense mutation in HFE (p.Tyr230Cys), and one mutation in the 5′-UTR of HAMP gene
(c.-25GNA).
The results reported here illustrate the usefulness of NGS for targeted iron metabolism-related gene panels, as a
likely cost-effective approach for molecular genetics diagnosis of non-classic HH patients. Simultaneously, it has
contributed to the knowledge of the pathophysiology of those rare iron metabolism-related disorders.






Hereditary hemochromatosis (HH; OMIM #235200) is an adult-
onset autosomal recessive disorder, common among Caucasians of
Northern European ancestry, which leads to progressive accumulation
of iron in parenchymal cells of multiple organs that can lead, ultimately,
to multi-systemic damage, if left untreated. HH is prevalently due to a
founder missense mutation, p.Cys282Tyr (c.845GNA) in the HFE gene
(6p21.3) [1]. This mutation, in the homozygous state, remains the
most frequentHHpatients' genotype. However, particularly in Southern
European populations, around one third of the patients with primary
iron overload do not present that genotype or the compoundHumana, Instituto Nacional de
6 Lisboa, Portugal.
austino).heterozygosity for the p.Cys282Tyr and the p.His63Asp mutations [2].
In fact, in addition to HFE, other iron metabolism-related genes may
be involved inHHdevelopment. The systemic regulation of iron homeo-
stasis is fundamentally achieved through the hepcidin/ferroportin axis.
Under homeostasis, hepcidin, a liver-secreted hormone, regulates the
efﬂux of iron from cells through its interaction with ferroportin, the
only known cellular iron exporter. While hepcidin control is relatively
well known, the regulation of hepcidin expression is a multifaceted
mechanism [3]. Consequently, there are different forms of HH resulting
frommutations in genes either involved in the hepcidin/ferroportin axis
or in the regulation of hepcidin expression: the HH type 2a and 2b
(OMIM#602390 and #61333), also known as Juvenile Hemochromato-
sis (JH), are due to mutation in HJV and HAMP genes, respectively; HH
type 3 (OMIM#604250), which is a disease mainly of adult onset but
where some juvenile forms can also bedescribed, is characterized by ge-
neticmutations in the TFR2 gene, andHH type 4 (OMIM#606069) is due
to mutations in the iron exporter ferroportin (SLC40A1 gene).
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variants of this gene have also been associated with HH [4–9].
With the advent of massive parallel DNA sequencing, such as the
next-generation sequencing (NGS), a number of challenges in the mo-
lecular genetics diagnosis of non-classic HH can be addressed. This
study aimed to explore the use of a fully customized amplicon-based
assay for targeted resequencing by NGS a panel of six HH-related
genes in patients presenting clinical and biochemical features compati-
ble with HHbut in which the classic HH-associatedHFE genotypeswere
not found. Thisway, several rare and novel variants were detected. Sub-
sequently, in silico as well as genotype/phenotype correlation studies
have facilitated the interpretation of the likely etiologic signiﬁcance of
some of the previously undescribed variants. Therefore, it was possible
to propose the novel variants play a pathogenic role in different types
of HH.
The results gathered in this study allowed to conclude that themerg-
ing of TruSeq Custom Amplicon (TSCA) methodology and NGS technol-
ogy can be applied to facilitate the detection of rare variants associated
with non-classic HH and, ultimately, to contribute to the understanding
of the pathophysiology of those clinical conditions.2. Materials and methods
2.1. Sample characterization
Patients enrolled in this study were selected by clinicians due to
their persistent increased iron status biomarkers, including serum ferri-
tin N300 μg/L and transferrin saturation N 60%, absence of evident envi-
ronmental risk factors for secondary iron overload (such as, alcohol and
hepatitis), and for having a negative ﬁrst level HH genetic test (which
means, absence of homozygosity for the HFE p.Cys282Tyr mutation or
of compound heterozygosity for p.Cys282Tyr and p.His63Asp).
Following appropriate informed consent, the study was performed
in 87 Portuguese patients (69 male and 18 female), presenting a mean
age of 51 years and a mean serum levels of iron-related parameters of:
iron 185 μg/dL, ferritin 940 μg/L, and transferrin saturation 76%.
Peripheral blood samples were collected in EDTA and used for DNA
extraction in a MagNA Pure nucleic acid extractor (Roche). DNA ﬂuo-
rometric quantitation assays were performed in a Qubit™ equipment
(Invitrogen) as recommended by the manufacturer. DNA sample con-
centrations were normalised to 25 ng/μL using puriﬁed bidistilled
water.
An extra set of ﬁve DNA samples previously analysed by Sanger se-
quencing and known to present a total 43 genetic alterations correspond-
ing to 14 different genetic variants in HFE, TFR2, HAMP, and SLC40A1
[8] were used as positive controls: HFE (rs1799945, rs2071303,
rs200706856, rs1572982, and rs1800758); TFR2 (rs41295912,
rs148902192, rs80338885, and rs2075674); HAMP (c.-25GNA);
SLC40A1 (rs2304704, rs4287798, rs1156835, and rs13008848).2.2. Panel design
A fully customizable, amplicon-based assay for targeted
resequencing was designed using the Design Studio 1.7 software
(Illumina). It is a user-friendly online tool that provides dynamic feed-
back to optimize design and region coverage. Automated data analysis
using the Illumina Amplicon Viewer software allowed to easily
reviewing the project data. The panel consisted of ninety-seven
amplicons with an average of 250 bp in length, covering a cumulative
target sequence of 12,115 bp including coding regions, exon/intron
junctions, promoters and untranslated regions (UTRs) of HFE, TFR2,
HJV, HAMP, SLC40A1 and FTL genes. The location of the designed
amplicons and their corresponding length are summarized in Supple-
mentary Table I.2.3. Next-generation sequencing
TSCA DNA libraries were prepared according to the manufacturer's
instructions and sequenced on a MiSeq instrument (Illumina) using
paired-end reads. Firstly, a training set of 5 samples (the positive con-
trols) was used to optimize the entire process of target ampliﬁcation
and sequencing. In this way it was veriﬁed that no true variant was
missed and that no other genetic alterations undetected by Sanger se-
quencing were observed. Then, the 87 uncharacterized DNA samples
were analysed. Sequence variants were identiﬁed using the built-in
data analysis workﬂow of theMiSeqReporter software (Illumina). Vari-
antswere called against the human genome reference hg19 for genomic
coordinates contained in themanifest ﬁle. Each variant was analysed in
respect to the total coverage (TC), quality (QUAL), variant frequency
(VF) and genotype (GT). A TC of 20 was used as a threshold for the ac-
ceptance of variants. Also an analysis of individual reads was made
using the Integrative Genomics Viewer software (http://www.
broadinstitute.org/igv/). The identiﬁed variants classiﬁed as likely path-
ogenic were conﬁrmed by Sanger sequencing using the BigDye Termi-
nator v1.1 Cycle sequencing kit (Applied Biosystems) and a 3130XL
Genetic Analyser (Applied Biosystems).
2.4. Bioinformatics studies
Genetic variants were considered novel when not annotated in any
of the following public databases: ENSEMBL (http: www.ensembl.org/
index.html), dbSNPs (http://www.ncbi.nlm.nih.gov/), GeneCards
(http://www.genecards.org/), and 1000 Genomes (http://www.
1000genomes.org).
Novel variants were named according to the Human Genome Varia-
tion Society (HGVS) recommendations (http://www.hgvs.org/
mutnomen/recs.html). Bioinformatics tools were used to predict their
deleterious effect. In the case of missense mutations the putative effect
on protein structure and function, as well as the study of multiple se-
quence alignment were analysed using the Polyphen-2 software
(http://genetics.bwh.havard.edu/pph2) and the HumDiv and HumVar
models. Polyphen-2 prediction is based on a number of features com-
prising the sequence, phylogenetic and structural information charac-
terizing the substitution. Also, the software Sorting Intolerant From
Tolerant (SIFT) which predicts whether an amino acid substitution af-
fects protein function based on sequence homology and the physical
properties of amino acids, was applied [10]. In what concerns splicing
variants their putative effect on the corresponding pre-mRNA splicing
was studied using the Human Splicing Finder, vs 3.0 software (http://
www.umd.be/HSF/). The MaxEntScan matrice based on the Maximum
Entropy Principle was also used. It is based on the approach for model-
ling the sequences of short sequence motifs such as those involved in
RNA splicing which simultaneously accounts for non-adjacent as well
as adjacent dependencies between positions. This method is based on
the most previous probabilistic models of sequence motifs such as
weight matrix models and inhomogeneous Markov models [11].
3. Results
3.1. Validation of the amplicon panel for next-generation sequencing
studies
A gene panel was designed in order to generate 97 amplicons, in-
cluding exons, intron/exon junctions, promoters and UTRs of of six
genes that we routinely screen by Sanger sequencing: HFE, TFR2, HJV,
HAMP, SLC40A1 and FTL (Supplementary Table I). The ampliﬁed targets
of approximately 250 bp were sequenced on the MiSeq equipment
(Illumina) and the resultant paired-end reads were analysed through
the built-in analysis pipeline. The sequences were aligned against
human genome reference hg19 using alignment and variant caller algo-
rithms in theMiSeqReporter software. Firstly, ﬁve known DNA positive
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mance of the NGSworkﬂow. These positive DNA controls contain a total
of 43 alterations corresponding to 14 different known genetic variants
in HFE, TFR2, HAMP and SLC40A1 genes. All genetic variants were cor-
rectly identiﬁed with 100% of concordance with Sanger sequencing re-
sults. However, 1 out of the 97 amplicons (≈1% in the panel) failed to
produce any reads (the amplicon no.33, corresponding to exon 17 of
TFR2, presented in the Supplementary Table I). Thus, this exon was
later analysed in all samples by Sanger sequencing.
3.2. Patients' genetic variants identiﬁcation and validation
Subsequently to the validation phase, the 87DNAs from the iron over-
load patients enrolled in this study matching the previously established
inclusion criteria were sequenced at high coverage on the MiSeq equip-
mentmaintaining the same experimental conditions as used for controls.
Through this approach a cumulative target sequence of 12,115 bp were
obtained. A total of 1241 molecular alterations were detected, corre-
sponding to 53 different genetic variants: 14 missense, 8 synonymous, 5
located at splicing regions, 1 premature translation initiation codon, 1 lo-
cated within an Iron-Responsive Element (IRE), and 24 common SNPs
known to integrate haplotypes in some of the mentioned genes (Table I
and Table II). Thirteen out of the mentioned 53 different identiﬁed vari-
ants were absent from the public databases (Table I). One of them, the
HAMP (c.-25GNA), although not annotated in databases had been already
found in the Portuguese population [8,12,13], and was considered a pri-
vate variant. Among these 13 novel/private variants, ﬁve were predicted
to be pathogenic by in silico studies and by genotype/phenotype correla-
tion: three are missense mutations in HFE (p.Tyr 230Cys), and TFR2
(p.Leu750Pro and p.Ala777Val); one is a splicing mutation in TFR2 gene
(c.967-1GNC); and one is located at the 5′-UTR of the HAMP gene (c.-
25GNA). Furthermore, another novel variantwas found in a conserved re-
gions of the IRE (c.-173CNG of FTL gene (Table I). All these variants were
validated by Sanger sequencing in separate PCRproducts (Supplementary
Fig. 1).
3.3. In silico studies of pathogenicity of the novel variants
The putative pathogenicity of the three novel missense mutations
was analysed using the bioinformatics tools, PolyPhen-2 and theHumDiv
andHumVarmodels aswell as SIFT. Concerning themutation c.689ANG
in exon 4 of HFE gene, p.Tyr230Cys in HFE protein, it was found in het-
erozygosity in a 51-year-old man presenting serum iron = 278 μg/dL,
ferritin = 651 ng/mL and transferrin saturation = 89%. This mutationTable I











Chr6:26092985ANG HFE 430:455 het 9069.08 Exon 4 c
Chr6:26092801TNC HFE 57:66 het 1325.07 Intron 3 c
Chr7:100229569CNG TFR2 0:453 hom 10655.17 Intron 7 c















Chr19:35773318GNA HAMP 62:49 het 874.57 5′UTR c
Chr1:145414708GNA HJV 240:218 het 4285.30 5′UTR c
Chr1:145415253GNA HJV 47:44 het 814.49 Intron 3 c
Chr1:145415769ANG HJV 59:62 het 1198.75 Exon 4 c
Chr2:190436342ANG SLC40A1 242:180 het 3470.70 Intron 5 c
Chr19:49468592CNG FTL 39:36 het 653.68 IRE_ 5′UTR c
Chr19:49469233TNG FTL 138:164 het 3347.00 Intron 2 cwas predicted by PolyPhen-2 to cause a possibly damaging effect at the
protein level because it presented a score of 0.857 [0.941 by HumDiv
(sensitivity 0.80; speciﬁcity 0.94) and 0.745 by HumVar (sensitivity
0.77; speciﬁcity 0.86)]. Concerning SIFT prediction it was classiﬁed as
deleterious at protein level with the score of 0. In addition, HFE amino
acid multiple sequence alignment around Tyr230, performed in
PolyPhen-2, has shown that this amino acid residue is conserved in 9
out 10 of the analysed mammalian species.
The missense mutation c.2249TNC located at exon 18 of TFR2 gene
(p.Leu750Pro) was found in homozygosity in a 56-year-old man, pre-
senting the following iron status: serum iron = 260 μg/dL, serum ferri-
tin = 2961 ng/mL and transferrin saturation of 84%. This variant was
predicted by PolyPhen-2 as probably damaging the protein because pre-
sented a score of 0.966 [0.963 by HumDiv (sensitivity 0.78; speciﬁcity
0.95) and 0.837 by HumVar (sensitivity 0.73; speciﬁcity 0.88)]. The
SIFT prediction was deleterious (score 0). The multiple sequence align-
ment by PolyPhen-2 revealed that the p.Leu750 is invariable between
species which is also in accordance with the hypothesis that this muta-
tion has a pathogenic effect on protein structure/function.
Concerning the other TFR2 variant also locatedwithin exon 18, TFR2:
c.2330CNT, p.Ala777Val, it was detected in two patients. It was found in
double heterozygosity with the p.His63Asp in a 36-year-old man pre-
senting a serum iron = 236 μg/dL and transferrin saturation of 86%,
and it was found in heterozygosity in a 65-year-old woman presenting
serum iron = 197 μg/dL and transferrin saturation = 73%. This muta-
tion was predicted by PolyPhen-2 to generate a probably damaging ef-
fect at protein level with the highest score of 1, including the scores of
1.000 by HumDiv and a score of 0.999 by HumVar. SIFT prediction was
deleterious with a score of 0. Also, TfR2 amino acid multiple sequence
alignment around Ala777, performed in PolyPhen-2, has shown this
amino acid is invariable between the studied 10 mammalian species.
In relation to the novel TFR2 splicing mutation, c.967-1GNC, it was
found in homozygosity in a 69-year-old man presenting: serum
iron = 198 μg/dL, ferritin = 1930 ng/mL, transferrin saturation =
100%. This variant is located in the last nucleotide of intron 7 of TFR2
gene affecting this acceptor splice site. The bioinformatics tool Human
Splicing Finder provided by the HSF matrices a score of 98.12 for the na-
tive acceptor sequence and a score of 69.18 for the mutant one. Thus, it
is observed a reduction of 30% of variation in the sequence recognition
scores, suggesting the wild type site broken and a deleterious effect on
splicing. As well, the MaxEntScan matrices gave for the wild type se-





























Genetic variants (already reported) in iron metabolism-related genes found by NGS in this study.





rs149342416 6:g.26087458GNC c.18GNC p.Arg6Ser Benign; uncertain signiﬁcance
rs62625319 6:g.26087551GNA c.76+35GNA Intron variant Likely benign
rs1799945 6:g.26090951CNG c.187CNG p.His63Asp Pathogenic; risk factor
rs1800730 6:g.26090957ANT c.193ANT p.Ser65Cys Pathogenic
rs2071303 6:g.26091108TNC c.340+4TNC Splice region variant Uncertain signiﬁcance
rs200706856 6:g.26091358GNA c.385GNA p.Asp129Asn Probably Pathogenic [8]
without ID 6:g.26092757ANT c.689ANT p.Tyr230Phe Likely benign [8]
rs1800562 6:g.26092913GNA c.845GNA p.Cys282Tyr Pathogenic
rs1800758 6:g.26093008GNA c.892+48GNA Intron variant Likely benign
rs2794717 6:g.26093069GNA c.893-50GNA Intron variant Likely benign
rs1800708 6:g.26093075TNC c.893-44TNC Intron variant Likely benign
rs201262562 6:g.26093246ANG c.1006+14ANG Intron variant Likely benign
rs1572982 6:g.26094139GNA c.1007-47GNA Intron variant Likely benign
TFR2
rs376955913 7:g.100640856GNA c.303CNT p.Tyr101= Synonymous/likely benign
rs148902192 7:g.100640678ANT c.473+8TNA Splice region variant Likely benign
rs34242818 7:g.100633241GNC c.714CNG p.Ile238Met Benign
rs41303474 7:g.100631978GNA c.967-33CNT Intron variant Likely benign
rs41303501 7:g.100629279CNT c.1364GNA p.Arg455Gln Uncertain signiﬁcance; risk factor
rs80338885 7:g.100628294CNT c.1403GNA p.Arg468His Pathogenic
rs139178017 7:g.100628224CNT c.1473GNA p.Glu491= Synonymous/likely benign
rs62625319 7:g.100627570GNA c.1767+7CNT Splice region variant Likely benign
rs2075674 7:g.100627408GNA c.1851CNT p.Arg617= Synonymous/likely benign
rs412295921 7:g.100627255CNG c.1995+9GNC Intron variant Likely benign
rs41295924 7:g.100627172CNT c.1995+92GNA Intron variant Likely benign
rs41295942 7:g.100621008CNT c.2255GNA p.Arg752His Benign
HJV
rs56025621 1:g.146019740GNC c.98-6CNG Splice region variant Uncertain signiﬁcance
HAMP
rs142126068 19:g.35282425CNT c.-153CNT 5′-UTR Likely benign
rs2293689 19:g.35284723CNT c.91-66CNT Intron variant Likely benign
rs104894696 19:g.35284999GNA c.212GNA p.Gly71Asp Risk factor
SLC40A1
rs13008848 2:g.189580558CNG c.-98GNC 5′-UTR Likely benign
rs11568351 2:g.189580468GNC c.-8CNG 5′-UTR Likely benign
rs4287798 2:g.189580350TNG c.43+68ANC Intron variant Likely benign
rs1439816 2:g.189579904CNG c.44-24GNC Intron variant Likely benign
rs11568344 2:g.189572846GNA c.387CNT p.Leu129= Synonymous/likely benign
rs2304704 2:g.189565451ANG c.663TNC p.Val221= Synonymous/likely benign
rs185040528 2:g.189563529CNT c.1402+55GNA Intron variant Likely benign
rs73980217 2:g.189563522CNA c.1402+62GNT Intron variant Likely benign
FTL
rs2230267 19:g.48965830TNC c.163TNC p.Leu55= Synonymous/likely benign
rs73046709 19:g.48966729CNT c.521CNT p.His174= Synonymous/likely benign
rs77793045 19:g.48966786GNT c.*51GNT 3′-UTR Likely benign
13R. Faria et al. / Blood Cells, Molecules and Diseases 61 (2016) 10–15In this study, one mutation was found in the homozygous state in
two siblings. The oldest sibling is a 49-year-old woman, presenting
amenorrhea at age 32, arthralgia and hepatomegaly. Her brother is a
47-year-old man who exhibits hypogonadotrophic hypogonadism.
Both patients present symptoms of iron overload since their youth
and both started phlebotomies at 24 years of age. In genotypic terms,
both patients are homozygotes for the HAMP: c.-25GNA variant located
within the 5′-UTR of the HAMP gene (Table I). This variant is not anno-
tated in the available public databases, however, it was already found in
our population. This G to A substitution gives rise to a novel out-of-
frame translation initiation codon (AUG), 25 nucleotides upstream to
the native one, which greatly disturbsHAMPmRNA genetic information
content [12,14].
It is noteworthy that although a NGS low coverage was obtained for
the 5′-UTR region of FTL, one variantwas detected in heterozygosity (al-
lelic depth of 39:36, Table I)whichwas subsequently validated by Sang-
er sequencing, c.-173CNG (Supplementary Fig. 1). This was found in a
55-year-old man presenting serum ferritin = 1291 ng/mL, transferrin
saturation = 84%. Cataracts have thus far not been reported.None of the above described likely pathogenic gene variants pre-
sented in Table I was found in a group of 50 individuals (100 alleles)
from the general Portuguese population so they should not be consid-
ered as common polymorphisms.
4. Discussion
In Northern European populations the high frequency of the HFE
p.Cys282Tyrmutationmakes the genetic diagnosis of HH relatively sim-
ple in themajority of the patients (a simple genetic test will conﬁrm the
diagnosis). However, genetic diagnosis of HH in Southern European
populations may prove more challenging. The diversity and rarity of
the mutations identiﬁed as causing iron overload have as consequence
that a single molecular test in not sufﬁcient to conclude the diagnosis.
In fact, using current technologies, genetic diagnosis involves Sanger se-
quencing of the entire coding region of one or more of the known HH-
related genes guided by phenotypic data. This is usually a costly and
time-consuming procedure. The development of NGS, as a high
throughput low-cost-per-basemethod, provided amuchgreater chance
14 R. Faria et al. / Blood Cells, Molecules and Diseases 61 (2016) 10–15of mutation identiﬁcation in iron overloaded patients who present a
negative HFE-ﬁrst level genetic test.
In this study, we have successfully sequenced a panel of six ironme-
tabolism-related genes, using 25ng of gDNAper sequencing run and the
amplicon panel designed by us provided the opportunity to analyse a
wide range of samples per MiSeq run. In fact, we have processed 87
DNA samples plus the 5 positiveDNA controls from the initial DNA sam-
ple to the analysed data in only a few days. Thus, TSCA provided an un-
precedented level of sample multiplexing, including convenient online
probe design and order, a stream line workﬂow and automatic data
analysis. We can conclude that the implementation of NGS in research
and subsequently as part of the routine clinical diagnosis may provide
a comprehensive molecular genetics method with a clinically compati-
ble throughput and turn-around time. However, establishing the clinical
relevance of NGS-detected novel genetic variants in an autosomal reces-
sive disorder with reduced penetrance and variable expressivity as HH,
remains a difﬁcult task, requiring further functional studies and interna-
tional collaborative efforts. In addition, although this technology facili-
tates the detection of the genetic cause of iron overload in some
patients with non-classic HH, there are still a few patients who have he-
reditary iron overload that are due to yet unidentiﬁed mutations in
genes or combinations of genes that have yet to be discovered.
Concerning the novel variant p.Tyr230Cys inHFE, bearing inmind its
location within the α3 domain of the protein and knowing this domain
is crucial to HFE interaction with the chaperone β2-microglobulin [15],
it is suggested that this change may generate an incorrect folding of the
protein and a deﬁcient presentation at the membrane surface, as was
proven to occur in result of other mutations located within this domain.
In fact, at least sevenmissensemutations causing diseasewere reported
at the HFE exon 4 (which codes for the α3 domain of the protein) in-
cluding the major p.Cys282Tyr mutation, making this exon a hot spot
formutations. In the case of thismutation, the tyrosine for cysteine sub-
stitution disrupts the formation of the disulﬁde bond that physiological-
ly occurs between Cys225 and Cys282 residues and that is essential for
HFE association with β2-microglobulin [1,16,17]. Therefore, the
p.Cys282Tyr-mutated HFE protein is unable to bind to the chaperone
β2-microglobulin and to be transported to cell surface where it would
interact with TfR1 and TfR2 in order to regulate hepcidin expression.
The same mechanism was proven to occur for some of the other mis-
sense mutations located at p.Cys282 neighbourhood, such as
p.Gln238Pro, p.Glu277Lys, p.Val295Ala [18–20]. In our case, the
p.Tyr230Cys-mutated HFE protein will probably allowed the creation
of a new disulﬁde bridge between the Cys225 and the novel Cys230
which might disturb the correct HFE/β2-microglobulin binding and
consequently the HFE correct folding and presentation at cell
membrane.
TfR2-related HH (HH type 3) is characterized by increased intestinal
iron absorption resulting in iron accumulation in the liver, heart, pan-
creas, and endocrine organs, as does HH type 1. The TfR2 protein is a
transmembrane homodimer homolog of TfR1 and it ismainly expressed
in the liver [21]. It is thought that TfR2 binds to HFE at cell surface and
acts as a body iron sensor of diferric transferrin, resulting in the upreg-
ulation of hepcidin production through a not yet fully understood sig-
nalling pathway [22–25]. Concerning the novel variants in TfR2, in the
case of p.Leu750Pro, proline is more hydrophilic than leucine and
gives rise to a less ﬂexible protein. Also, the p.Ala777Val seems to
strongly perturb the protein structure and function because valine is
an aliphatic and hydrophobic molecule that tends to favour the forma-
tion of helical structures. Moreover, both mutations are located within
the dimerization domain of the TfR2 protein, near the carboxyl-terminal
end, and were predicted by PolyPhen-2 and SIFT as being deleterious.
Several other missense variants located at this domain were classiﬁed
as pathogenic, such as p.Gly792Arg, and p.Thr740Met, because the dis-
ruption of that domain is generally associated with protein severe loss
of function [26,27]. In fact, this domain is crucial for the Fe2-Tf-TfR2-
HFE complex interactions. Nevertheless, another TFR2missense variantlocated in the same TfR2 domain (the c.2255GNA, p.Arg752His) is clas-
siﬁed as a frequent polymorphismwith a genetic modiﬁer capacity [26,
28,29]. In our study, the variant c.2255_ allele A was found with a fre-
quency of 0.033 in the group of iron overloaded patients, whereas it
was found with a frequency of 0.02 in 50 Portuguese individuals from
the general population. However, this difference is not signiﬁcant
(p=0.892;Qui-square test). A similar frequencyhas been also reported
for the European general population, 0.021 (1000 Genomes project).
Also in the TFR2 gene, we have found a novel splicing variant, the
c.967-1GNC which is located in the last nucleotide of intron 7. This sub-
stitution signiﬁcantly reduces the consensus value of the wild type
splice site (−30% of variation by HSF and−78% by MaxEnt) meaning
that this acceptor splice site is broken and cannot be recognised by the
splicing machinery. Therefore, the presence of the variant may favour
the exon 8 skipping and a consequent frameshift in the reading frame.
As exon 8 is 140 nucleotides in long, its skipping originates a premature
stop codon (PTC) at codon 304, as predicted by Translated Tool of ExPASy
software (http://web.expasy.org/translate/), andmay trigger the corre-
sponding mRNA degradation by the nonsense mediated decay mecha-
nism. Our patient presents this novel variant in homozygosity, TFR2:
c.[967-1GNC)]; [967-1GNC)], which supports his HH type 3 phenotype.
As far as we know, there are only four splicing mutations in TFR2 gene
classiﬁed as pathogenic and are associated with HH type 3: c.1606-
8ANG, c.1538-2ANG, c.2137-1GNA, and c.614+4ANG [26–28,30,31].
Concerning the private HAMP c.-25GNA variant, it seems to have
reached some prevalence in the Portuguese population. The ﬁrst two
cases of JH due to homozygosity for this mutation were reported by
Matthes and co-workers [12] in two Portuguese siblings. Then, another
two JH patients were reported, also presenting homozygosity for the
same mutation, in two unrelated families of North [13] and Centre of
Portugal [8]. In this study, we report another two Portuguese siblings,
with JH phenotype and homozygosity for the same mutation. They de-
scend from a ﬁrst-cousin marriage in a village from Southern Portugal
(Amareleja, Moura) and do not seem to be directly related with the
ﬁrst ones. This variant was not found in a group of 50 individuals (100
alleles) from the general Portuguese population, so it cannot be consid-
ered a common polymorphism.
Under physiological conditions, ferritin synthesis is ﬁnely regulated
at the translational level by iron availability. It is achieved by high-afﬁn-
ity interaction between cytoplasmic mRNA binding proteins (the Iron-
Regulatory Proteins, IRP) and a cis-acting non-coding mRNA stem-
loop structure (the IRE). The 5′UTR of FTL mRNA presents an IRE
where upon binding IRPs represses translation. We have found in the
5′-UTR of the FTL gene a variant (c.-173CNG) that is located at the 5′
stem of the IRE, position+27. As far as we know, there is no previously
described single nucleotide substitution affecting this nucleotide. The
only similar casewas described in an Italian familywith high serum fer-
ritin levels and juvenile cataract. But, here the molecular lesion
consisted in a six nucleotide deletion from positions +22 to +27 [32].
Our patient presented a severe iron overload phenotype which
progressed to a fatal hepatocellular carcinoma. There was no report of
cataracts in his clinical history. Thus, we cannot establish a clear geno-
type/phenotype correlation in this case. Also his relatives are not avail-
able to be recruited for a family study.
5. Conclusion
The recent development of NGS allows practical, manageable, and
cost-effective analysis of the non-classic HH cases, proving to have sig-
niﬁcant utility when conventional testing has failed to identify the un-
derlying molecular basis of the disease. As far as we know, only two
studies have been published concerning the application of NGS to atyp-
ical iron disorders [33,34]. The identiﬁcation and study of novel ironme-
tabolism-related mutations are important steps forward to improve the
knowledge of the HH genetic basis heterogeneity and of the pathophys-
iology of the different types of HH. Clinically, it is also important because
15R. Faria et al. / Blood Cells, Molecules and Diseases 61 (2016) 10–15whilst the treatment of themore common forms of iron overload is sim-
ilar, differential diagnosis remains important in atypical cases in which
speciﬁc treatment and/or monitoring options are recommended.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2016.07.004.
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